Ticker history: TIVC became VBIO (Tivic Health Systems Inc) on . Earlier news and filings retain their original names and dates. View TIVC history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VBIO SEC filings page.
This page shows Valion Bio, Inc. (VBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a financing-funded development business: large losses persisted while new capital enlarged assets and research spending.
Return on equity moved from-223.1% in FY2024 to-52.8% in FY2025, a large improvement on paper. Yet FY2025 still produced a net loss of$8.878M alongside operating cash flow of-$6.999M , so the better ratio mainly reflects a larger capital base rather than operating profitability.
The balance sheet expanded through financing rather than operating cash: financing cash flow reached
This remains a development-stage cost structure. In FY2024, research and development was
Financial Health Signals
We do not publish a peer-relative financial health score for Valion Bio, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Valion Bio, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
Valion Bio, Inc. reported a net loss of $8.9M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Valion Bio, Inc. reported an operating loss of $7.9M against $146K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Valion Bio, Inc.'s EBITDA was -$6.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Valion Bio, Inc. reported a net loss of $7.1M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Valion Bio, Inc. recorded an outflow of $5.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Valion Bio, Inc. held $2.1M in cash against $7.4M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Valion Bio, Inc.'s quarterly ROE was -167.3% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 114.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 111.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Valion Bio, Inc. invested $2.7M in research and development in Q2 2026. This represents an increase of 312.8% from the same quarter a year earlier. Against the prior quarter it is up 45.8%.
Valion Bio, Inc. invested $57K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1800.0% from the same quarter a year earlier. Against the prior quarter it is up 714.3%.
Not reported for Q2 2026.
VBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $146K+15.9% | $86K-38.6% | $70K-79.0% | $180K-49.6% | $126K-55.3% |
| Cost of Revenue | N/A | N/A | N/A | $291K+254.9% | $32K-70.9% | $20K-88.0% | $419K+19.0% | $82K-52.9% |
| Gross Profit | N/A | N/A | N/A | -$145K-429.5% | $54K+80.0% | $50K-70.1% | -$239K-4880.0% | $44K-59.3% |
| R&D Expenses | $2.7M+312.8% | $1.9M+453.4% | $1.3M+285.3% | $858K+103.3% | $655K+116.9% | $335K+30.9% | $333K-7.5% | $422K+25.2% |
| SG&A Expenses | $3.7M+263.6% | $3.8M+262.8% | N/A | $1.5M+40.6% | $1.0M+2.9% | $1.0M-25.1% | N/A | $1.1M-31.2% |
| Operating Income | -$6.4Mn/m | -$5.6Mn/m | N/A | -$2.5Mn/m | -$1.7Mn/m | -$1.4Mn/m | -$1.5Mn/m | -$1.4Mn/m |
| EBITDA | -$6.1Mn/m | -$5.6Mn/m | N/A | -$2.5Mn/m | -$1.7Mn/m | -$1.4Mn/m | -$1.5Mn/m | -$1.4Mn/m |
| Interest Expense | $691Kn/m | $648Kn/m | N/A | N/A | $0 | $0 | N/A | N/A |
| Net Income | -$7.1Mn/m | -$6.2Mn/m | -$2.8Mn/m | -$2.6Mn/m | -$1.9Mn/m | -$1.5Mn/m | -$1.5Mn/m | -$1.4Mn/m |
| EPS (Basic) | -$2.17 | -$2.23 | -$1.35 | -$1.97 | -$2.19 | -$2.52 | -$1.46 | -$3.93 |
| EPS (Diluted) | N/A | N/A | N/A | N/A | -$2.19 | -$2.52 | N/A | -$3.91 |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | 881,294 | 596,368 | N/A | 364,184 |
Not reported in any period shown, so not listed: Income Tax.
VBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $32.5M+620.3% | $38.2M+911.8% | $31.6M+1026.0% | $6.2M+83.5% | $4.5M-5.7% | $3.8M+14.9% | $2.8M-45.6% | $3.4M-51.6% |
| Current Assets | $3.4M+83.6% | $8.7M+586.1% | $13.0M+392.8% | $3.7M+18.2% | $1.8M-60.5% | $1.3M-55.4% | $2.6M-43.3% | $3.2M-51.0% |
| Cash & Equivalents | $2.1M+78.0% | $7.2M+978.5% | $12.6M+531.6% | $3.5M+57.6% | $1.2M-67.9% | $669K-59.9% | $2.0M-41.0% | $2.2M-57.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $750K+165.0% | $750K+145.1% | $0-100.0% | $4K-99.5% | $283K-63.1% | $306K-60.5% | $319K-57.8% | $731K-21.2% |
| Accounts Receivable | N/A | N/A | N/A | $19K+111.1% | $13K-18.8% | $13K-82.4% | $69K-60.3% | $9K-93.1% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $3.5M | $3.5M | $3.5Mn/m | N/A | N/A | N/A | $0 | N/A |
| Total Liabilities | $28.2M+3338.1% | $19.7M+2554.1% | $14.8M+5344.9% | $2.8M+402.7% | $821K+38.9% | $741K-34.6% | $272K-82.8% | $560K-54.9% |
| Current Liabilities | $3.0M+271.0% | $2.6M+252.9% | $646K+137.5% | $638K+13.9% | $821K+38.9% | $741K-25.3% | $272K-80.6% | $560K-44.0% |
| Non-Current Liabilities | $25.2Mn/m | $17.1Mn/m | $14.2Mn/m | $2.2Mn/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% |
| Long-Term Debt | $7.4M | $6.9M | $6.5Mn/m | N/A | N/A | N/A | $0 | N/A |
| Total Equity | $4.2M+15.2% | $11.1M+264.4% | $16.8M+562.6% | $3.4M+20.5% | $3.7M-12.0% | $3.0M+41.0% | $2.5M-29.2% | $2.8M-50.8% |
| Retained Earnings | -$66.5Mn/m | -$59.0Mn/m | -$52.6Mn/m | -$49.6Mn/m | -$47.0Mn/m | -$45.0Mn/m | -$43.5Mn/m | -$42.1Mn/m |
VBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.3Mn/m | -$5.0Mn/m | -$2.3Mn/m | -$2.0Mn/m | -$1.8Mn/m | -$889Kn/m | -$1.4Mn/m | -$1.4Mn/m |
| Depreciation & Amortization | $358K+35700.0% | $4K+300.0% | $3Kn/m | $0-100.0% | $1K0.0% | $1K0.0% | $0-100.0% | $1K0.0% |
| Stock-Based Compensation | $133K-24.9% | $208K+108.0% | N/A | $138K+137.9% | $177K+227.8% | $100K+85.2% | N/A | $58K+20.8% |
| Capital Expenditures | $57K+1800.0% | $7Kn/m | $25Kn/m | $10K | $3K | $0 | $0n/m | N/A |
| Free Cash Flow | -$5.3Mn/m | -$5.0Mn/m | -$2.3Mn/m | -$2.0M | -$1.8M | -$889K | -$1.4Mn/m | N/A |
| Investing Cash Flow | -$57Kn/m | -$7Kn/m | -$149Kn/m | -$10K | -$20K | -$526K | $0n/m | N/A |
| Financing Cash Flow | $231K-90.2% | -$44K-153.7% | $11.6M+887.4% | $4.3Mn/m | $2.4M-28.7% | $82Kn/m | $1.2Mn/m | -$97K-102.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | -99.3%-134.2pp | 62.8%+41.4pp | 71.4%+21.4pp | -132.8% | 34.9%-3.4pp |
| Operating Margin | N/A | N/A | N/A | -1700.7% | -1951.2% | -1967.1% | -857.2% | -1135.7% |
| Net Margin | N/A | N/A | N/A | -1778.1% | -2245.3% | -2145.7% | -820.6% | -1135.7% |
| Return on Equity | -167.3%-114.9pp | -56.1%-6.6pp | -17.0%+41.3pp | -76.0%-25.5pp | -52.4%-22.2pp | -49.5%+19.3pp | -58.3%+4.4pp | -50.5%-20.0pp |
| Return on Assets | -21.9%+21.0pp | -16.2%+23.5pp | -9.0%+43.6pp | -41.7%+0.5pp | -42.8%-16.4pp | -39.8%+5.3pp | -52.6%-9.1pp | -42.2%-17.0pp |
| Current Ratio | 1.11-1.1x | 3.31+1.6x | 20.13+10.4x | 5.86+0.2x | 2.24-5.6x | 1.70-1.1x | 9.70+6.4x | 5.65-0.8x |
| Debt-to-Equity | 1.74 | 0.62 | 0.38+0.4x | N/A | N/A | N/A | 0.00 | N/A |
| Liabilities-to-Equity | 6.65+6.4x | 1.78+1.5x | 0.88+0.8x | 0.82+0.6x | 0.22+0.1x | 0.24-0.3x | 0.11-0.3x | 0.200.0x |
| Asset Turnover | N/A | N/A | N/A | 0.020.0x | 0.020.0x | 0.02-0.1x | 0.060.0x | 0.040.0x |
| FCF Margin | N/A | N/A | N/A | -1374.0% | -2127.9% | -1270.0% | -758.3% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Valion Bio, Inc. VBIO | FY2025 | N/A | -$8.9M | N/A | $1.0M | — |
| Scinai Immunotherapeutics Ltd. SCNI | FY2025 | $1.3M | -$8.3M | N/A | $1.0M | 54/100 |
| GeoVax Labs, Inc. New GOVX | FY2025 | $2.5M | -$21.5M | N/A | $985K | 46/100 |
| Biodexa Pharmaceuticals plc BDRX | FY2025 | N/A | -$8.6M | N/A | $983K | — |
| PMGC Holdings Inc. ELAB | FY2025 | $590K | -$7.7M | N/A | $1.3M | — |
| Bone Biologics Corp BBLG | FY2025 | N/A | -$3.1M | N/A | $910K | — |
Where Valion Bio, Inc. Ranks
Frequently Asked Questions
No, Valion Bio, Inc. (VBIO) reported a net loss of $18.8M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $8.9M.
Valion Bio, Inc. (VBIO) had EBITDA of -$7.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Valion Bio, Inc. (VBIO) had $12.6M in cash and equivalents against $6.5M in long-term debt.
Valion Bio, Inc. (VBIO) has a return on equity of -52.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Valion Bio, Inc. (VBIO) recorded an outflow of $7.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Valion Bio, Inc. (VBIO) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Valion Bio, Inc. (VBIO) had $31.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Valion Bio, Inc. (VBIO) invested $38K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Valion Bio, Inc. (VBIO) invested $3.1M in research and development during fiscal year 2025.
Valion Bio, Inc. (VBIO) had a current ratio of 20.13 as of fiscal year 2025, which is generally considered healthy.
Valion Bio, Inc. (VBIO) had a debt-to-equity ratio of 0.38 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Valion Bio, Inc. (VBIO) had a liabilities-to-equity ratio of 0.88 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Valion Bio, Inc. (VBIO) had a return on assets of -28.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Valion Bio, Inc. (VBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Valion Bio, Inc. (VBIO) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $1.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Valion Bio, Inc. (VBIO) held $12.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Valion Bio, Inc. (VBIO) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Valion Bio, Inc. (VBIO) reported a net loss of $8.9M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Valion Bio, Inc. (VBIO) reported an operating loss of $7.9M against $146K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.